Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:12:34 29/06/2024 am IST			5-day change	1st Jan Change
2.875 ^USD	-1.54%		-10.06%	-32.28%

03/06	Vgxi Inc. Announces Strategic Partnership with Sutro Biopharma Inc. to Support Growing Clinical Pipeline	CI
13/05	Sutro Biopharma Q1 Loss Widens, Revenue Rises	MT

Sutro Biopharma : 39th Annual JP Morgan Healthcare Conference – Presentation

January 15, 2021 at 03:52 am IST

310 Utah Ave Suite 150
South San Francisco, CA 94080
650-392-8412

Attachments

Original document
Permalink

Disclaimer

Sutro Biopharma Inc. published this content on 14 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 January 2021 22:21:01 UTC

Latest news about Sutro Biopharma, Inc.

Vgxi Inc. Announces Strategic Partnership with Sutro Biopharma Inc. to Support Growing Clinical Pipeline	03/06	CI
Sutro Biopharma Q1 Loss Widens, Revenue Rises	14/05	MT
Earnings Flash (STRO) SUTRO BIOPHARMA Posts Q1 Revenue $13M	14/05	MT
Sutro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
BofA Securities Starts Sutro Biopharma With Buy Rating	08/05	MT
Sutro Biopharma, Inc. Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial	30/04	CI
Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating	03/04	MT
Truist Securities Adjusts Price Target on Sutro Biopharma to $18 From $25, Keeps Buy Rating	03/04	MT
Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors	02/04	CI
Ipsen: worldwide licensing agreement with Sutro Biopharma	02/04	CF
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	02/04	MT
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup	27/03	DJ
Wedbush Adjusts Sutro Biopharma's Price Target to $8 From $12, Maintains Outperform Rating	26/03	MT
Sutro Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
Transcript : Sutro Biopharma, Inc. - Special Call	05/01
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC	05/01	CI
Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from NASDAQ Biotechnology Index	15/12	CI
Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023	12/12	CI
Vaxcyte Exercises Option for Manufacturing Rights Agreement With Sutro Biopharma; Sutro Shares Jump Premarket	28/11	MT
Vaxcyte Exercises Option for Manufacturing Rights Agreement With Sutro Biopharma	28/11	MT
Vaxcyte, Inc. Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control over Manufacturing and Development of Cell-Free Extract for Its Vaccine Candidates	28/11	CI
Sutro Biopharma Promotes Jane Chung to Newly Created Position of COO	22/11	MT
Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer	22/11	CI
Piper Sandler Adjusts Price Target on Sutro Biopharma to $12 From $18, Maintains Overweight Rating	15/11	MT
Earnings Flash (STRO) SUTRO BIOPHARMA Reports Q3 Revenue $16.9M	14/11	MT

Chart Sutro Biopharma, Inc.

Duration

Period

More charts

Company Profile

Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Companyâs advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Sutro Biopharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.92 USD

Average target price

12.3 USD

Spread / Average Target

+321.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SUTRO BIOPHARMA, INC.	-32.28%	239M
VERTEX PHARMACEUTICALS INCORPORATED	+16.96%	122B
REGENERON PHARMACEUTICALS, INC.	+20.21%	113B
ARGENX SE	+18.95%	26.49B
BIONTECH SE	-23.68%	19.4B
GENMAB A/S	-19.03%	16.24B
BEIGENE, LTD.	-20.36%	15.4B
WUXI APPTEC CO., LTD.	-46.14%	15.15B
SAREPTA THERAPEUTICS, INC.	+65.11%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.53%	13.52B

Bio Therapeutic Drugs